Recently published studies reveal advances in precision and performance, driven largely by labs in China

Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery

BioCentury’s editors also discuss recommendations for early stage rare disease drug development

Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo

Caribou selected a de-risked target and modality to take on multiplexed editing

Editas set out to bring a new technology — CRISPR-Cas9 — to indications not served by existing therapeutic modalities

An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy

Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned